●] Shares FUSION PHARMACEUTICALS INC. COMMON SHARES UNDERWRITING AGREEMENTUnderwriting Agreement • June 22nd, 2020 • Fusion Pharmaceuticals Inc. • Biological products, (no disgnostic substances) • New York
EMPLOYMENT AGREEMENTEmployment Agreement • June 22nd, 2020 • Fusion Pharmaceuticals Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Employment Agreement (“Agreement”) is made between Fusion Pharmaceuticals Inc. (“Parent Company”), Fusion Pharmaceuticals US, Inc., a Delaware corporation and US subsidiary of the Parent Company (the “Company”), and John Crowley (the “Executive”) and is effective as of the closing of the first underwritten public offering of the equity securities of the Parent Company pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “Effective Date”). Except with respect to the Restrictive Covenants Agreement and the Equity Documents (each as defined below), this Agreement supersedes in all respects all prior agreements between the Executive and the Parent Company and/or the Company regarding the subject matter herein, including without limitation (i) the Employment Agreement between the Executive and the Parent Company dated February 19, 2019 and revised February 22, 2019 (the “Prior Agreement”), and (ii) any offer letter, employment agreement or s
FUSION PHARMACEUTICALS INC. [FORM OF] DIRECTOR INDEMNIFICATION AGREEMENTDirector Indemnification Agreement • June 22nd, 2020 • Fusion Pharmaceuticals Inc. • Biological products, (no disgnostic substances) • Delaware
This Indemnification Agreement (“Agreement”) is made as of [Date] by and between Fusion Pharmaceuticals Inc. (the “Company”), a corporation existing under the Canada Business Corporations Act (the “CBCA”), and [Director Name] (“Indemnitee”).
FUSION PHARMACEUTICALS INC. [FORM OF] OFFICER INDEMNIFICATION AGREEMENTOfficer Indemnification Agreement • June 22nd, 2020 • Fusion Pharmaceuticals Inc. • Biological products, (no disgnostic substances) • Delaware
This Indemnification Agreement (“Agreement”) is made as of [Date] by and between Fusion Pharmaceuticals Inc. (the “Company”), a corporation existing under the Canada Business Corporations Act (the “CBCA”), and [Officer Name] (“Indemnitee”). 1
EMPLOYMENT AGREEMENTEmployment Agreement • June 22nd, 2020 • Fusion Pharmaceuticals Inc. • Biological products, (no disgnostic substances) • Ontario
This Employment Agreement (“Agreement”) is made between Fusion Pharmaceuticals Inc. (the “Company”), and John Valliant (the “Executive”) and is effective as of the closing of the first underwritten public offering of the equity securities of the Company pursuant to an effective registration statement under the Securities Act of 1933, as amended (United States) (the “Effective Date”). Except with respect to the Restrictive Covenants Agreement and the Equity Documents (each as defined below), this Agreement supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation the Employment Agreement between the Executive and the Company dated October 12, 2018 (the “Prior Agreement”).
